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Context: Adipose tissue is an important site for extragonadal steroid hormone biosynthesis 
through the expression and activity of P450 aromatase, 11β-hydroxysteroid dehydrogenase 
(HSD) 1, and 17β-HSDs. The contribution of steroid hormones produced by adjacent adipose 
tissue for the progression and survival of breast tumors is unknown.
Objective: To quantify estrogens (estradiol, estrone) and glucocorticoids (cortisol, cortisone) 
in breast adipose tissue from both healthy and diseased women and their relationships with 
adiposity indices and breast cancer prognostic markers.
Design and setting: Breast adipose tissue was collected at time of surgery.
Patients: Pre- and postmenopausal women undergoing partial mastectomy for treatment of 
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Interventions: Relative estrogen and glucocorticoid amounts were determined by liquid 
chromatography tandem mass spectrometry.
Results: The targeted steroids were reliably detected and quantified in mammary adipose 
tissues. Women with ER+/PR+ tumor had higher relative estradiol amount than women with 
ER–/PR– tumor (P < .05). The ratio of estradiol-to-estrone was higher in lean women than in 
women with a body mass index (BMI) ≥ 25 kg/m2 (P < .05). Mixed-model analyses showed 
that estradiol, cortisone, and cortisol were negatively associated with tumor size (P < .05). 
Relationships between glucocorticoids and tumor size remained significant after adjustment 
for BMI. The cortisol-to-cortisone ratio was negatively associated with tumor stage (P < .05) 
independently of BMI.
Conclusions: We reliably quantified estrogens and glucocorticoids in breast adipose tissue from 
healthy women and women suffering from breast cancer. Our findings suggest that smaller 
breast tumors are associated with higher relative amounts of estradiol and cortisol in adipose 
tissue. (J Clin Endocrinol Metab 105: e1504–e1516, 2020)
Key Words:  estradiol, estrone, cortisol, cortisone, breast cancer, adiposity
B eing overweight or obese is a well-known risk factor for postmenopausal breast cancer (1, 2). 
Obesity is also linked to a poorer prognosis in women 
with breast cancer regardless of their menopausal status 
(1, 3, 4). Women with obesity have more aggressive tu-
mors, higher mortality rates and incidence of metas-
tases, and increased risk of recurrence (1, 5–8). Central 
obesity, as measured by waist circumference (WC), is an 
emerging risk factor for both pre- and postmenopausal 
breast cancer (9). Furthermore, the efficacy of chemo-
therapy, radiotherapy, surgery, and endocrine therapy 
is reduced in women with obesity and possibly more 
so with increased visceral fat accumulation (10–14). 
The mechanisms underlying higher risk and reduced 
treatment efficacy are not fully understood. Altered se-
cretion of adipokines, growth factors, and steroids by 
dysfunctional mammary adipose tissue may contribute 
to a proinflammatory, growth-promoting microenviron-
ment for cancer cells (15). Recent evidence from human 
studies has shown that local breast adipose tissue does 
present an altered biological profile, as described above, 
concomitant with body mass index (BMI) increases (16–
21). Reports from Dannenberg and collaborators have 
shown that mean adipocyte cell size from breast adipose 
tissue was positively associated with BMI and increased 
aromatase expression and inflammation markers such 
as crown-like structures and was also related to meno-
pausal status (19, 20).
Expression and activity of several steroidogenic en-
zymes present in adipose tissue have been linked to 
increased adiposity (22). For example, higher rates of 
androgen-to-estrogen conversion through aromatiza-
tion in adipose tissue (22) have been proposed as a mech-
anism for the obesity-related increase in breast cancer 
risk. Findings from our group suggest that known estro-
genic 17β-hydroxysteroid dehydrogenase (HSD) (type 
1, 7, and 12)-mediated conversion of estrone (E1) to es-
tradiol (E2) is 5 times higher in differentiated adipocytes 
than in preadipocytes (23). Increased mean adipocyte 
size is associated with higher expression and activity of 
11β-HSD type 1, which locally converts cortisone to ac-
tive cortisol through oxoreductase activity (24, 25).
Despite their well-known anti-inflammatory ef-
fects, glucocorticoids (GCs) could contribute to 
breast cancer initiation, progression, and survival via 
the activation of the glucocorticoid receptor (GR) or 
by increasing aromatase expression via the GC re-
sponse element (GRE) on exon I.4 of the CYP19A1 
gene (26). Moreover, HSD11B1  expression increases 
with estrogen receptor β (ERβ) activation (27). In a 
rodent model of breast cancer, increased GC nurtured 
the transition from DCIS (ductal carcinoma in situ) 
to IDC (invasive ductal carcinoma) while administra-
tion of RU-486 was able to partially block this effect, 
that is, prevent breast cancer progression to IDC (28). 
Considering the slow turnover of GCs in adipose tissue 
(29), there is biological plausibility for autocrine and 
paracrine effects of active GCs, such as cortisol, in the 
tumoral microenvironment.
Hence, steroid dynamics in breast adipose tissue and 
cancer appear to involve more than overexpression and 
increased activity of aromatase. We currently have very 
little information about the relative importance of adi-
pose tissue dysfunction markers such as altered steroid 
conversion to tumor progression and aggressiveness 
or patient prognosis. Moreover, considering the com-
plexity of potential enzymatic hormone conversion in 
adipose tissues, direct measurement of active hormones 
and their precursors has become highly relevant.
Liquid chromatography followed by tandem mass 
spectrometry (LC-MS/MS) is recognized as the gold 
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however, tissue steroids are more difficult to measure 
than those in plasma due to the complexity of the matrix 
and the need to homogenize uniformly. Measurements 
are confounded by the low abundance and the poor ion-
ization profile of steroids as well as the higher concen-
trations of lipids in adipose tissue than in plasma, which 
result in higher susceptibility of so-called matrix effects. 
We aimed to characterize the relationship of local cor-
tisol and E2 as well as inactive steroid cortisone and 
main E2 precursor E1 with adiposity and prognostic 
markers in a sample of women with or without breast 
cancer. We hypothesize that independently of meno-
pausal status (1) relative E2 and cortisol breast adipose 
tissue amounts as well as the ratio E2:E1 and cortisol 
on cortisone are increased with adiposity; (2) worst clin-
ical breast cancer features, such as tumor stage, size and 
grade are associated with lower relative adipose tissue 
steroid amounts; and (3) relative estrogen amounts are 
increased in women with ER+/PR+ tumors. We also in-
vestigated if these relationships were independent of 
total adiposity, that is, reflecting the microenvironment 
or a characteristic of the adiposity state.
Methods
Study sample and data collection
The study protocol was approved by the Research Ethics 
Committees of Laval University Medical Center (DR-002-
136). All patients signed a written, informed consent prior 
to surgery. Breast adipose tissue was obtained from women 
undergoing partial or total mastectomy for treatment of breast 
cancer (n = 17) or reduction mammoplasty (n = 6). Fresh tissue 
specimens were acquired from residual resected breast tissues 
that were not required for clinical diagnosis at least 1 cm away 
from the tumor margins. Information on clinicopathologic 
and anthropometric factors was collected from in-person 
interviews, phone call interviews, and/or medical records.
Laboratory methods
Cell sizing.  Breast adipocyte size was measured as previously 
described (30, 31) in formalin-fixed adipose tissue. Briefly, 250 
breast adipocytes from 10 randomly chosen areas at ×40 mag-
nification using Calopix software (Tribvn) were measured for 
each tissue sample in a blinded fashion.
Liquid chromatography-tandem mass 
spectrometry 
Standards and solvents. E1 and E2 were obtained from 
Steraloids, Inc. (Newport, RI). Cortisone, cortisol, and 
iodomethane (≥99%) were from Sigma-Aldrich, Inc. (Dorset, 
UK). 1-(2,4-dinitro-5-fluorophenyl)-4-methylpiperazine 
(PPZ) was obtained from TCI chemicals (Chuo-ku, Tokyo, 
Japan). High-performance liquid chromatography (HPLC) 
grade glass distilled solvents (acetone; ethyl acetate [EtOAc]; 
water) were from Fisher Scientific UK Limited (Loughborough, 
UK). Analytical reagent (AR) grade ethanol (EtOH) and 
HPLC grade glass distilled solvents (acetonitrile; methanol 
[MeOH]), and LCMS grade (acetonitrile  [(CH3)2CO]; 
formic acid [FA; ≥98%]; water) solvents were from VWR 
(Lutterworth, UK).
Instrumentation.  Cortisone, cortisol, E1, and E2 were 
measured by LC-MS/MS, using a UHPLC Shimadzu Nexera 
X2 system (UK) coupled to a Sciex QTRAP® 6500+ (SCIEX, 
Warrington, UK) equipped with an electrospray ionization 
interface (ESI). Mass spectrometry conditions were previously 
described in conjunction with ion spray voltage (5500 V) and 
source temperature (500°C) (32).
Sample preparation.  Following enrichment of frozen adi-
pose tissue samples (~200 mg) with 3 internal standards (IS), 
9,11,12,12-[2H4]-cortisol (D4F5  ng; Cambridge Isotopes 
Laboratory, Thaxted, UK), 2,3,4-[13C3]-17β-estradiol and 
2,3,4-[13C3]-estrone (
13C3E2, 
13C3E1 respectively; 5  ng; 
Sigma-Aldrich, Inc., St. Louis, MO), analytes were extracted 
as described below.
Briefly, frozen adipose tissue samples were homogen-
ized (Model Pro 200, ProScientific, Inc, Monroe, CT) in 
EtOH:EtOAc (1 mL; 1:1) and immediately frozen on dry ice 
and stored at –80°C overnight. The following morning, sam-
ples were thawed on wet ice and sonicated (8 × 15-second 
bursts with 1-minute gaps; Ultrasonic cleaner, Branson 
Ultrasonic Inc, Danbury, CT). Samples were subjected to 
centrifugation (3200g, 45 minutes, 4°C; Heraeus Megafuge 
16R, ThermoFisher Scientific, Germany). The supernatant 
was transferred into a new glass tube and dried down under 
oxygen-free nitrogen (OFN; 60°C). Samples were resus-
pended in aqueous MeOH (30% v/v, 5  mL). Solid-phase 
extraction was carried out after conditioning C18 Sep-
Pak columns (12  cc, 2  g; Waters, Wilmslow, UK; MeOH 
(2 × 10 mL), followed by H2O (2 × 10 mL)). The adipose 
extract was loaded, and the column was washed with H2O 
(10 mL) followed by aqueous MeOH (5%, 10 mL). Steroids 
were eluted with MeOH:CH3CN (1:1, 10 mL). The eluent 
was dried down under OFN at 60°C prior to derivatization 
of estrogens. Generation of 1-(2,4-dinitrophenyl)-4,4-
dimethylpiperazinium (MPPZ) derivatives of E1 and E2 has 
already been described (32–34). Derivatization was carried 
out by incubating (1 hour, 60°C) with [(CH3)2CO] (70 µL), 
NaHCO3 (10 µL, 1M, Sigma-Aldrich, Inc., St. Louis, MO) 
and PPZ (10 µL, 1 mg/mL, dissolved in (CH3)2CO) followed 
by the addition of CH3I (100 µL), and further incubation (2 
hours, 40°C) as previously described (33, 34). Samples were 
dissolved in H2O:CH3CN (70 µL; 70:30) and transferred to 
LC vials.
Liquid chromatography parameters.  Following injection 
(30 µL), analytes were separated on an ACE 2 Excel C18-PFP 
(150 × 2.1 mm, 2 μm; HiChrom, Reading, UK, 40°C) column. 
The elution process started with mobile phase compositions 
of 90:10 H2O with 0.1% FA (solution A) and CH3CN with 
0.1% FA (solution B) which was maintained for 1 minute. 
This was followed by an 11-minute linear gradient to 50% 
solution B, which was maintained for 2 minutes, before re-
turning to 10% solution B at 15 minutes and maintained for 3 
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Linearity and lower limit of quantitation.  Blank samples 
and aliquots containing estrogens (5, 7.5, 10, 15, 25, 50, 100, 
200, 500, 1000 pg/sample), GCs (50, 75, 100, 150, 250, 500, 
1000, 2000, 5000, 10 000 pg/sample), and IS (500 pg) were 
analyzed by LC-MS/MS. Calibration curves were plotted as 
the peak area ratio (standard/IS) versus amount of analytes 
(GCs or estrogens). Calibration lines of best fit were accept-
able if the regression coefficient, r, was >0.98. Weightings of 
1/x were used for all 4 steroids. Linearity and lower limit of 
quantitation LLOQs were 50 pg, 15 pg, 100 pg, and 75 pg 
for E2, E1, cortisol, and cortisone, respectively. Values below 
the confirmed LLOQ were calculated as LLOQ divided by 3: 
the lowest acceptable signal-to-noise ratio. The values were 
then converted to pmol/kg according to the weight of the cor-
responding adipose tissue sample. This transformation was 
performed to avoid null values to calculate steroid ratios as 
described below.
Calculated ratios
All steroid amounts were converted into pmol/kg. Those 
values were then used to calculate product and substrate 
ratios, as described below. The ratio of cortisol:cortisone was 
used as a marker of 11β-HSD1 enzyme activity. The ratio of 
E2:E1 was used as a marker of estrogenic 17β-HSD enzyme 
activity.
Gene expression
Tissues were homogenized in Qiazol buffer (Qiagen, 
Germantown, MD, USA) and total RNA was extracted using 
the RNeasy mini kit on-column DNase (Qiagen, Hilden, DE) 
treatment following the manufacturer’s instructions. First-
strand cDNA synthesis was accomplished using 1 µg of RNA 
in a reaction containing 200 U of Superscript IV Rnase H-RT 
(Invitrogen Life Technologies, Burlington, Canada). cDNA 
corresponding to 20 ng of total RNA was used to perform 
fluorescent-based real-time polymerase chain reaction (PCR) 
quantification using the LightCycler 480 (Roche Diagnostics, 
Mannheim, DE). Reagent LightCycler 480 SYBRGreen 
I Master (Roche Diagnostics, Indianapolis, IN) was used as 
described by the manufacturer. The conditions for PCR reac-
tions were 45 cycles, denaturation at 95°C for 10 seconds, an-
nealing at 58–60°C for 10 seconds, elongation at 72°C for 14 
seconds, and then 72°C for 5 seconds (reading). Oligoprimer 
pairs were designed by GeneTool 2.0 software (Biotools 
Inc., Edmonton, Canada) and their specificity was verified 
by blast in the GenBank database. The synthesis was per-
formed by IDT (Integrated DNA Technology, Coralville, IA) 
(Table 1). Normalization was performed using the following 
reference genes: ATP synthase O subunit (ATP5O), hypo-
xanthine guanine phosphoribosyl transferase 1 (HPRT1), 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Quantitative real-time PCR measurements were performed by 
the CHU de Québec Research Center (CHU) Gene Expression 
Platform, Quebec, Canada, and were compliant with the 
Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) guidelines.
Statistical analyses
Differences in breast adipocyte diameter between women 
with breast cancer (cases) and women without breast cancer 
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by Student’s t-test. Cell size frequency distribution differences 
between case and control women or according to menopausal 
status were assessed by the Kolmogorov–Smirnov (KS) test. 
Women were subdivided in categories of BMI (lean [<25 kg/
m2] or overweight and obese [≥25  kg/m2]) or according to 
their estrogen and progesterone receptor (ER/PR) status. 
Relative hormone amounts or ratios between those sub-
groups were assessed by Student’s t-test. Satterthwaite ap-
proximation was used when variances were deemed unequal 
according to a conservative folded F statistic (P < .10). Exact 
P-values computed using nonparametric Wilcoxon tests 
showed similar results. Women were subdivided according to 
their respective tumor size, according to tertiles of the distri-
bution. A mixed model was performed to evaluate the rela-
tionship between relative hormone amounts and tumor size 
(in tertiles or continuous; as determined by the best AIC fit 
for the model), grade (categorical), and stage (categorical). 
A  repeated statement was incorporated into the model to 
account for the nonconstant variance among the residuals, 
that is, specifying a variance component covariance struc-
ture in the model. Non-normally distributed variables were 
log-transformed to achieve normality and linearity. Models 
were further adjusted for BMI (as a continuous variable) 
to account for total adiposity. Adjustments for menopausal 
status and current use of hormonal derivatives (as combined 
indicator variables) were also performed as they are identified 
as confounders in the breast cancer literature. Spearman cor-
relation coefficients were computed to assess the relationship 
between relative steroid amount, prognostic factors, and rela-
tive expression of genes. P < .05 was considered significant. 
All statistical analyses were performed with SAS software 
(SAS Institute, Cary, NC).
Results
Table 2 shows the characteristics of the study sample. 
Women were overweight with a median BMI of 25.6 kg/
m2 and a median age of 55  years. Postmenopausal 
status was equally balanced across case and control 
women. Table  3 presents the clinicopathological fea-
tures of premenopausal and postmenopausal breast 
cancer patients. Most women presented with a unilat-
eral breast lesion. Breast tumors were mainly of ductal 
histology (82%). Only 1 woman presented a HER2+ 
tumor and 13 women had an ER+/PR+ tumor. Half of 
the women had stage 2 breast cancer as classified by 
TNM score (35).
Table 2. Clinical characteristics of the women with breast cancer and control women.
Women
Variables (median, [Q1-Q3]) All (n = 23) Controls (n = 6) Cases (n = 17)
Age (years) 55.0 (50.1–62.9) 53.7 (44.9–57.5) 55.9 (53.2–63.2)
Menopausal status    
 Premenopausal n (%) 8 (35) 2 (33) 6 (35)
 Postmenopausal n (%) 15 (65) 4 (67) 11 (65)
Anthropometrics    
 BMI (kg/m2) 25.6 (24.3–28.2) 27.1 (24.3–29.4) 25.4 (24.5–26.8)
 WC (cm) − − 94 (86–99)
 Breast adipocyte mean diameter (µm) 75.5 (67.3–87.5)a 87.9 (86.2–89.5) 74.1 (66.1–80.3)b
Hormonal derivatives    
 Current oral contraceptive use (yes) n (% of premenopausal) 6 (75) 1 (50) 5 (83)
 Current HRT use (yes) n (% of postmenopausal) 5 (33) 2 (50) 3 (27)
Abbreviations: BMI, body mass index; HRT, hormonal replacement therapy; WC, waist circumference.
an = 22, bn = 16. 
Table 3. Characteristics of the tumor.
Characteristics n (%) Premenopausal (n = 6) Postmenopausal (n = 11) All (n = 17)
Lesion    
 Unilateral 5 (83.33) 10 (90.91) 15 (88.24)
 Bilateral 1 (16.67) 1 (9.09) 2 (11.76)
Histology    
 Ductal 6 (100.00) 8 (72.73) 14 (82.35)
 Othersa 0 (0.00) 3 (27.27) 3 (17.65)
Receptor status    
 ER+/PR+ 5 (83.33) 8 (72.73) 13 (76.47)
TNM status    
 0 0 (0.00) 3 (27.27) 3 (17.65)
 1 2 (33.33) 4 (36.36) 6 (35.29)
 2 4 (66.67) 4 (36.36) 8 (47.06)
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
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Women with or without breast cancer were com-
parable for primary clinical characteristics, except for 
mean fat cell size which was 13.3  µm higher in the 
control women (t-test, P = .0072). This difference was 
also shown by the adipocyte size distribution curve 
comparison (KS, P = .0041) (Fig. 1A). Postmenopausal 
women had a 9.7 µm higher mean adipocyte size than 
premenopausal women as well as a right-shifted adi-
pocyte size distribution; however, this difference was 
not statistically significant (Fig.  1B). The distribution 
remained similar when considering only cancer cases 
(Fig. 1C).
Quantification of steroids
Table 4 shows relative adipose tissue steroid amounts 
and calculated ratios. Relative E1 and cortisol amounts 
were quantified in each of the 23 samples of mammary 
adipose tissue. E2 was below the limit of quantification 
for 2 samples. Cortisone was below the limit of quanti-
fication for 5 samples, 4 of which were obtained from 
control women.
HSD11B1 mRNA abundance was positively correl-
ated with the cortisol:cortisone ratio (r = 0.49; P = .0198) 
and negatively associated with relative cortisone amount 
(r = –0.49; P = .0221). In women with ER+/PR+ tumor, 
HSD17B12 transcript amount (r = 0.58; P = .0479) was 
correlated with relative E1 amount in breast adipose 
tissue. HSD17B12, HSD17B7, or CYP19A1 were not 
correlated with relative E2 amount. Women with cancer 
had higher expression of HSD17B12 mRNA than con-
trols (P = .0231). Relative E2 amount was positively as-
sociated with ESR2 (ERβ) mRNA expression (r = 0.61; 
P = .0358), but not ESR1 (ERα) mRNA expression in 
women with ER+/PR+ tumor. In women with breast 
cancer, abundance of CYP19A1 transcript was posi-
tively correlated with HSD11B1 mRNA expression 
(r = 0.54; P = .0326).
Adiposity
The ratio of E2 to E1 was higher in lean women than 
in women with a BMI ≥ 25 kg/m2 (P = .0335) (Fig. 2A) 
(postmenopausal, n  =  15, P  =  .0072; premenopausal, 
n = 8, P = NS) in the entire cohort, even if CYP19A1 
expression was higher in women with a BMI ≥ 25 kg/m2 
(P < .05). This difference remained significant when con-
sidering only cancer cases (P = .0393, n = 17), or only 
ER+/PR+ patients (P =  .0436, n = 13). The difference, 
although the same magnitude as above, was no longer 
statistically significant when considering ER+/PR+ pa-
tients with invasive carcinoma (stage ≥ 1) (P =  .0900, 
n = 11). Relative E2 amount was higher in lean women 
Figure 1. Size distribution of breast adipocytes. (A) Comparison 
between control and case women (t-test, P = .0072; KS, 
P = .0041; n = 22). (B) Comparison between premenopausal and 
postmenopausal women (t-test, P = .0510; KS, P = .0864; n = 22). (C) 
Comparison between premenopausal and postmenopausal women 
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than in women with obesity and overweight in cancer 
cases (P  =  .0494) (Fig.  2B) (postmenopausal, n  =  11, 
P = .0325; premenopausal, n = 6, P = NS). cancer cases 
(P = .0494) (Fig. 2B). There was no difference in cortisol 
and cortisone between lean  women and women with 
obesity and overweight (data not shown).
Breast cancer clinical features
Relative adipose tissue E2 amount (log-transformed) 
was inversely associated with tumor size (categorical 
variable) (Fig. 3A) (P = .0281, n = 17) (postmenopausal, 
n = 11, P = .0283; premenopausal, no convergence), but 
this relationship did not reach statistical significance 
when tumor size was treated as a continuous variable 
(β = –0.0199, P =  .1089, n = 17). Further adjustment 
for menopausal status and use of hormonal derivatives 
did not alter the results (P = .0488, n = 17) whereas the 
relationship was no longer significant after adjusting for 
BMI (P = .1569, n = 17) or when considering only pa-
tients with invasive carcinoma (stage ≥ 1) (P =  .1157, 
n = 14). Including only women with ductal carcinoma 
generated similar effect size. Although the adjusted 
models were no longer significant, the nonadjusted 
model remained significant (data not shown). CYP19A1 
mRNA expression was positively correlated with tumor 
size (r  =  0.49; P  <  .05), whereas expression of ESR1 
(ERα) mRNA was negatively associated with this vari-
able (r = –0.54; P = .0296). There was no relationship 
between  relative adipose tissue estrogen amounts and 
tumor stage or tumor grade in our sample.
The ratio of cortisol to cortisone was lower in 
women with cancer than in control women (P < .0001). 
This difference was driven by higher relative cortisone 
amount and not lower relative cortisol amount. In fact, 
relative cortisone amount was higher in cancer patients 
than in control patients (P = .0055). These differences 
remained when combining controls with women with 
ER–/PR– breast cancer who shared similar character-
istics (Table 5), and comparing them with women with 
ER+/PR+ tumor (P = .0097 and P = .0171, respectively) 
(data not shown).
No difference was detected between control women 
and cancer-positive women with respect to cortisol (data 
not shown). Both log-transformed cortisol and corti-
sone amounts were inversely associated with tumor size 
(β = – 0.01873, P = .0007) and (β = –0.05048, P < .0001) 
independent of BMI, menopausal status, and current 
use of hormonal derivatives (β = –0.02135, P = .0027) 
Table 4. Relative amounts of steroid and associated ratios in adipose tissue.
Women
Steroids (median, [Q1-Q3]) All (n = 23) Controls (n = 6) Cases (n = 17) *P-value
Cortisone (pmol/kg) 5501 (1829–16 748) 326 (298–1829) 7817 (2811–16 748) .0055
Cortisol (pmol/kg) 22 671 (16 040–33 719) 22 142 (16 040–46 171) 22 671 (18 473–32 688) .5697#
Estrone (pmol/kg) 3744 (2847–9899) 7855 (3062–18 998) 3744 (2514–7415) .1611
Estradiol (pmol/kg) 2320 (1537–4160) 2747 (1796–2937) 2306 (1537–4160) .4211
Ratio cortisol:cortisone 4.13 (2.47–15.09) 42.28 (15.09–56.09) 3.35 (2.26–5.54) <.0001
Ratio estradiol:estrone 0.46 (0.32–0.66) 0.54 (0.15–0.65) 0.44 (0.33–0.63) .6059
*Student t-test P-values calculated with log-transformed variables. #Satterthwaite adjusted P-value
Figure 2. Adiposity and estrogens in breast adipose tissue. (A) 
Difference of the estradiol:estrone ratio according to body mass 
index (BMI) status using 25 kg/m2 as a cut-off (P = .0335, n = 23). 
(B) Difference of relative estradiol amounts in women with cancer 
according to BMI status using 25 kg/m2 as a cut-off (P = .0494, 
n = 17). Data on graphs are mean. Open circles represent 
premenopausal women data points and filled circles represent 
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and (β = –0.03636, P < .0001) (Fig. 3B and 3C) when 
tumor size was treated as a continuous variable. When 
we stratified according to menopausal status, the 
mixed-models remained significant for postmenopausal 
women (n = 11) (Fig. 3B and 3C; P = .0055, P < .0001) 
but did not converge for premenopausal women 
(n  =  6). Those relationships were still significant 
when including only patients with invasive tumors 
(cortisol: β  =  –0.02376, P  =  .0078; βadj  =  –0.02977, 
P  =  .0079, and cortisone: β  =  –0.03328, P  <  .0001; 
βadj = –0.03650, P < .0001). Contrary to estradiol, cor-
tisone and cortisol were not associated with tumor size 
Figure 3. Breast cancer clinical features and relative breast adipose tissue steroid amounts. (A) Mixed-model regression between relative estradiol 
amount (log-transformed) and tertiles of tumor size adjusted for menopausal status and current intake of hormonal derivatives (β 2 = –0.9785, 
β 3 = –1.1197; P = .0488). (B) Mixed-model regression between relative cortisol amount (log-transformed) and tumor size (continuous) adjusted 
for body mass index (BMI), menopausal status, and current intake of hormonal derivatives (β = –0.02135, P = .0027). (C) Mixed-model regression 
between relative cortisone amount (log-transformed) and tumor size (continuous) adjusted for BMI, menopausal status, and current intake of 
hormonal derivatives (β = –0.03636, P < .0001). (D) Mixed-model between cortisol:cortisone ratio (log-transformed) and tumor stage adjusted for 
BMI (β 2 = –1.8720, β 3 = –1.8316; P = .0410). (E) Difference in relative estradiol and estrone amounts in ER–/PR– vs ER+/PR+ women (P = .0134 
and P = .0454). Data on graphs are mean. n = 17. Open circles represent premenopausal women data points and filled circles represent 
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(all TNM stages included or with only invasive tumors) 
(P = .0904 and P = .1894). Tumor stage was negatively 
associated with cortisol:cortisone ratio independent of 
BMI (β2 = –1.8720, β3 = –1.8316; P = .0410) (Fig. 3D) 
(postmenopausal, n  =  11, P  =  .0660; premenopausal, 
n = 6, P = .3096). In sensitivity analyses, including only 
women presenting a ductal carcinoma histology pheno-
type, the models generated  similar results (data not 
shown). There was no relationship between relative adi-
pose tissue GC amounts and tumor grade in our sample.
Higher relative amounts of E2 and E1 were de-
tected in adipose tissue of women with ER+/PR+ tumor 
than in women with ER–/PR– tumor (P  =  .0163 and 
P  =  .0134, respectively) (Fig.  3E) (postmenopausal, 
n = 11, P = .1077 and P = .4324, respectively; premeno-
pausal, no convergence).
Discussion
To our knowledge, this is the first study to report a 
LC-MS/MS quantification method combining analysis 
of cortisone, cortisol, E1, and E2 extracted from breast 
adipose tissue from both healthy women and women 
with breast cancer. Several lines of evidence showed 
that adipose tissue might play an active role in tumor 
initiation and progression (18, 36, 37). As such, the 
notion of an active cross-talk between adipose and 
tumor cells has been put forward in the literature (15, 
38, 39). In vitro uptake of E1, E2, and cortisol from 
culture media by female abdominal adipose tissue ex-
plants was reported as being more than 2-fold lower 
than progesterone and testosterone, highlighting the 
possible contribution of steroid conversion in adipose 
tissue as a source of estrogens and GC for the tumor 
(40). Yet, the contribution of adipose tissue to relative 
steroid hormone amounts and their possible actions re-
main to be fully elucidated. Most of the steroidogenic 
pathways have been studied directly in breast tumors 
or in vitro. Reports of endogenous steroid hormones 
in breast adipose tissue mostly comprise analyses of 
estrogens (E1 and E2) and their corresponding fatty 
acyl-esters as well as androgen precursors, namely 
androstenedione and testosterone (41–44). Of note, 
a recent study characterized more than 20 steroids, 
including androgens, progestogens, and estrogens in 
breast adipose tissue by GC-MS/MS (45). A  limita-
tion of that study is the lack of data regarding normal 
breast adipose tissue from healthy controls.
Quantification of steroids
We have been able to quantify these 4 steroids in most 
of our breast adipose samples. Interestingly, we found 
similar ranges in relative amounts for estrogens as those 
reported by Honma and collaborators in breast cancer 
tissue, using LC-MS/MS (46). These findings suggest 
that breast adipose tissue is a potent source of sex hor-
mones for the tumor. One of the strengths of our study 
is the use of stable isotope dilution LC-MS/MS instead 
of the historically used ELISAs (enzyme-linked immuno-
sorbent assays). ELISAs for steroid measurements have 
several drawbacks such as nonspecific antibody inter-
actions, inconsistent reproducibility, and inadequate 
sensitivity (47). Moreover, they usually require separate 
assays for each compound of interest, demanding a 
large quantity of tissue. Using 3 stable isotope-labelled 
standards in our protocol allowed us to normalize for 
loss of analytes during the extraction process.
Contrary to our hypothesis, our data, reported as 
pmol/kg of whole adipose tissue, showed a decrease in 
the ratio of E2:E1 and a decrease of E2 with increasing 
adiposity, as assessed with the BMI, suggesting little im-
pact of aromatase conversion per mass unit in adipose 
tissue. This can also be explained by the higher affinity 
of androstenedione as a substrate for aromatase com-
pared with testosterone, as previously reported (48). 
Marchand et al. reported that higher circulating E2 con-
centration is directly associated with increased fat mass 
(49). Simpson and colleagues reported that increased 
aromatization in obesity was due to a higher number of 
cells and not to higher conversion activity per adipose 
tissue mass unit (50). Our results are also consistent 
with another study where the authors found a posi-
tive correlation between the E1:E2 ratio in visceral fat 
and BMI in postmenopausal women (51). Contrary to 
Savolainen-Peltonen, we found that HSD17B12 mRNA 
expression is higher in adipose tissue from cancer pa-
tients than in controls (44). We cannot exclude that the 
lower relative amount of E2 observed in adipose tissue 
of overweight and obese women are due to increased 
uptake by the tumor cells as previously proposed by 
Savolainen-Peltonen et al. (44). However, we observed 
this difference in our entire sample and with all women 
with cancer, including those with ER– status. Effect size 
Table 5. Clinical characteristics of the women with 
ER–/PR– breast cancer and control women.
Variables (median, 
[Q1-Q3]) Control (n = 6) ER–/PR– (n = 4)
Age (years) 53.7 (44.9–57.5) 54.9 (53.6–60.29)
BMI (kg/m2) 27.1 (24.3–29.4) 26.0 (25.5–26.6)
Premenopausal n (%) 2 (33) 1 (25)
Postmenopausal n (%) 4 (67) 3 (75)
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were not modified when stratification by ER+/PR+ was 
performed.
We were unable to find a significant association be-
tween BMI and relative cortisol amount in breast adi-
pose tissue. We acknowledged that this may be due to 
our limited sample size. However, we found lower and 
nonquantifiable cortisone amount  in breast adipose 
tissue of our control women (4 out of 6). Our group of 
control women had higher mean adipocyte size than our 
women with cancer. This is not surprising, as our con-
trol women tended to have higher BMI than the women 
with cancer, although not statistically significant prob-
ably because of our small sample. The adipocyte size 
difference reported between pre- and postmenopausal 
women is similar to the findings of Iyengar and collab-
orators (19). The lower amount of cortisone could be 
partially explained by a higher activation rate of cor-
tisol or a lower inactivation of cortisol to cortisone by 
11β-HSD1, because our gene expression results sug-
gest that HSD11B1 expression is positively associated 
with the cortisol:cortisone ratio and negatively associ-
ated with the cortisone relative amount. These results 
are consistent with previous findings from our team 
which showed that 11β-HSD1 activity and expression 
is positively associated with adipocyte size, at least in 
the abdominal subcutaneous and omental depots (24, 
25). A previous study with obese subjects undergoing 
bariatric surgery has indeed found lower amount of cor-
tisone in adipose tissue of obese subjects before weight 
loss and when compared with control with no difference 
in adipose tissue relative cortisol amount among those 
groups (52). No difference in tissue relative amount of 
cortisol could be explained by concomitant higher clear-
ance by 5α-reductase, also increased in obesity (53). 
However, our data showed no decrease in cortisone 
with higher BMI, which suggests a different catabolism 
of cortisol and cortisone in women with breast cancer.
Some steroids were previously proposed to be in-
creased in adipose tissue during obesity such as cor-
tisol, which could also act as an immune suppressor 
in breast tissue. As reported by Cirillo et al., many dif-
ferent tumor types produce active cortisol which in-
hibits tumor-specific CD8+ T proliferation in vitro (54). 
Infiltration of CD8+ cells was linked to improved cancer-
specific survival by Mohammed and collaborators (55). 
However, breast cancer was one of the types of cancer 
not showing any difference between HSD11B1/2 ex-
pression between cancer and matched normal epithelial 
tissues, which suggest a paracrine, possibly by adjacent 
adipose tissue, instead of an autocrine effect by cortisol 
(54). In the same order of ideas, immunohistochemistry 
of 11β-HSD1 showed a presence of the enzyme in 64% 
of breast tumors and 97% of matched adjacent tissue 
(56) and GR protein amount was higher in breast tumor 
than in normal epithelial tissue (57). Increases in GC, 
particularly cortisol, can induce aromatase expression 
via the GRE on exon I.4 (26). On the other hand, cor-
tisol via binding to GR is an activator of the estrogen 
sulfotransferase, which inactivates estrogens by adding 
a sulfate group and limiting its binding to ER (58).
We did observe higher relative cortisone amount 
in adipose tissue from women with cancer with no 
change in cortisol. As per our initial hypothesis, we 
did observe a decrease in relative estradiol, cortisol, 
and cortisone amounts according to tumor size and 
a decrease in cortisol:cortisone ratio with increasing 
tumor stage. As stated previously, the decrease in es-
tradiol, but not estrone, with tumor size could repre-
sent an increased uptake by the tumor cells (43). The 
higher cortisol:cortisone ratio in patients with cancer 
than in control women and the further decrease of 
this ratio with tumor stage point to a dual effect of 
GCs in breast cancer related to stage of the disease. 
Increases in cortisol:cortisone ratio at the lower 
stages could increase estrogen production via activa-
tion of aromatase, but at a later stage, decreases in 
cortisol:cortisone could be explained by a negative 
feedback loop through increased estrogen production 
by the tumor and a concomitant lower expression of 
HSD11B1. However, we were unable to demonstrate 
a relationship between cortisol:cortisone ratio with 
E2:E1 ratio or E2 and E1 in our sample, contrary to 
previous results in visceral adipose tissue, but similar 
to results in subcutaneous tissue (51).
Despite our relatively low number of patients in both 
groups, we found that median E2 adipose tissue level 
was higher in women ER+/PR+ than ER–/PR–. Hennig 
et  al. reported higher adipose tissue E2, androstene-
dione, and androsterone levels in women with ER+ 
breast cancer than those ER–, but no difference in E1 
or any of the other androgens and progestogens (45). 
Falk et al. measured adipose tissue sex steroids by radio-
immunoassay and found a significant difference only for 
testosterone and a trend for higher E2, E1, and andro-
stenedione concentration in ER+/PR+ than in ER–/PR– 
samples (41). We found that  relative E2 amount was 
associated with  ESR2 (ERβ) mRNA, but not that of 
ESR1 (ERα) in women with ER+/PR+ tumor. ESR2 ex-
pression is known to be increased with E2 production, 
not ESR1, either suggesting a negative feedback or no 
effect depending on depot origin (59). ESR2 is only ex-
pressed in mature adipocytes in adipose tissue whereas 
ESR1 is present in both the stromal vascular fraction 
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has been linked with adipose tissue dysfunction (61). 
However, a relationship with adipocyte cell size and 
ESR1 expression was not observed in our study.
Limitations of our study are the relatively low 
number of participants which is counterbalanced by 
the wide range of BMI and prognostic marker values 
of our cohort. Of note, our total sample number is in 
the same order of magnitude as previous literature on 
breast adipose tissue steroid measurements (41–44), 
representing the difficulty in obtaining those samples 
for research purposes. Moreover, we have included in 
our analysis, control samples, namely samples from 
healthy women.
Data on steroid concentration in breast adipose 
tissue from healthy control and women with cancer 
are scarce in the literature. Most publications inves-
tigated this relationship in postmenopausal women 
(41, 42, 44) with the exception of Hennig et al. (45), 
who did include premenopausal women (n = 6 out of 
51) in their analyses. They did not, however, separate 
according to menopausal status due their low number 
of premenopausal women. We acknowledge the poten-
tial difference in hormone metabolism between pre- 
and postmenopausal women. Because the main source 
of estrogens shifts from gonads to peripheral tissues 
in menopause, we adjusted for menopausal status and 
age in our analysis. We also performed stratification 
to further alleviate concerns about the influence of 
menopausal status, but these analyses should be inter-
preted with caution. It should be noted that inference 
in our study is limited to postmenopausal women, as 
our number of premenopausal women did not allow 
us to investigate fully their steroid concentration as a 
separate group. Most of our findings were still signifi-
cant when including only postmenopausal women. Of 
note, tissue steroid concentration in our study did not 
vary as a function of menopause. Our cohort repre-
sents normal demographics in breast cancer, that is, in-
creased prevalence in older, postmenopausal women. 
Hence, we suggest that these findings are relevant in 
this context.
The use of a cross-sectional design does not allow for 
causal inferences and we acknowledge that there might 
be reverse causality as higher tumor stage and size may 
cause changes in steroid metabolism rather than the op-
posite. Another constraint is that we cannot quantify the 
distance from the tumor at which the adipose tissue sam-
ples were taken. However, as the defined margins were 
all included in paraffin blocks for clinicopathological 
assessment directly at the hospital, we can attest that 
our adipose samples were taken at least 1 cm from the 
tumor extremities. Hennig et al. reported no difference 
between steroid concentration between 2 sample loca-
tions (<0.5 cm and >5 cm), except for E2 (45). Owing 
to the standard of care and acceptable limit margins in 
Quebec for clinicopathological assessment, it was not 
possible to include adipose tissue <0.5 cm away from 
the tumor in a research project. Therefore, the variation 
of E2 due to the relative distance from the tumor was 
likely limited.
Conclusion
We were able to quantify estrogens and GCs in breast 
adipose tissue from both healthy women and women 
suffering from breast cancer. There is clear indication 
that steroid hormone metabolism is different among 
those 2 subgroups. Moreover, relative amounts of sex 
steroids in adipose tissue appear to be related to BMI, 
especially for E2, whereas differences in relative GC 
amounts  appear to be more closely related to cancer 
progression. As such, relative estradiol amount was 
lower in women with larger tumors independently of 
age and menopausal status and relative GC amounts 
were negatively associated with tumor size, independ-
ently of age, menopausal status and BMI.
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